Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHELLE SEWON MIN

Allopathic & Osteopathic Physicians Dermatology

NPI
1194176354
CMS profile
2154245
Location
IRVINE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$7,837.35

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,600.00 1
Travel and Lodging $1,468.58 4
Food and Beverage $668.78 18
Education $99.99 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $7,338.26 15
ABBVIE INC. $164.49 3
PFIZER INC. $132.78 2
Janssen Biotech, Inc. $99.99 1
LEO Pharma Inc. $67.77 2
Janssen Scientific Affairs, LLC $34.06 1

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHELLE SEWON MIN

NPI 1194176354 · CMS profile ID 2154245

Allopathic & Osteopathic Physicians / Dermatology

IRVINE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194176354?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHELLE SEWON MIN, NPI 1194176354, CMS profile ID 2154245. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194176354?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MICHELLE SEWON MIN, NPI 1194176354, CMS profile ID 2154245. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194176354?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MICHELLE SEWON MIN, NPI 1194176354, CMS profile ID 2154245, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1194176354?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $7,837.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $27.5612/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053505709 CMS
E.R. Squibb & Sons, L.L.C. $2.0012/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016282445 CMS
E.R. Squibb & Sons, L.L.C. $78.9912/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016282451 CMS
E.R. Squibb & Sons, L.L.C. $5,600.0011/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016282427 CMS
LEO Pharma Inc. $40.2110/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053505703 CMS
E.R. Squibb & Sons, L.L.C. $348.1910/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015010929 CMS
E.R. Squibb & Sons, L.L.C. $60.0010/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015010879 CMS
E.R. Squibb & Sons, L.L.C. $30.0010/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015010887 CMS
E.R. Squibb & Sons, L.L.C. $51.6310/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015010895 CMS
E.R. Squibb & Sons, L.L.C. $30.0010/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015010903 CMS
E.R. Squibb & Sons, L.L.C. $693.2110/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015010913 CMS
E.R. Squibb & Sons, L.L.C. $348.1910/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015010921 CMS
ABBVIE INC. $26.5009/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997923819 CMS
E.R. Squibb & Sons, L.L.C. $3.2908/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016282291 CMS
E.R. Squibb & Sons, L.L.C. $1.6208/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016282297 CMS
Janssen Biotech, Inc. $99.9907/10/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988182733 CMS
E.R. Squibb & Sons, L.L.C. $5.5007/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016282245 CMS
ABBVIE INC. $25.8706/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997923817 CMS
E.R. Squibb & Sons, L.L.C. $32.4406/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016282215 CMS
ABBVIE INC. $112.1206/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997923815 CMS
Janssen Scientific Affairs, LLC $34.0603/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988434143 CMS
E.R. Squibb & Sons, L.L.C. $53.2001/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016282097 CMS
PFIZER INC. $74.8301/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050392353 CMS
PFIZER INC. $57.9501/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050574397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,230.51 15
PY2020 $238.47 4
PY2021 $99.00 1
PY2022 $2,787.23 3
PY2023 $7,837.35 24
PY2024 $1,088.64 13
PY2025 $31,470.54 46

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $284,823.16 20
PY2024 Principal investigator $173,600.06 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650342
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650344
Principal investigator 1 Boehringer Ingelheim International GmbH $7.20 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650346
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650348
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650350
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650352
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650354
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650356
Principal investigator 1 Boehringer Ingelheim International GmbH $70.38 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650358
Principal investigator 1 Boehringer Ingelheim International GmbH $10.50 12/17/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650360
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $31.11 09/19/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220794125
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9.92 07/28/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220794123
Principal investigator 1 Boehringer Ingelheim International GmbH $7,440.40 07/07/2025 Non-covered Recipient Entity
University Of California Irvine
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220650340
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,981.28 04/30/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Polymyositis No dispute reported 06/30/2026 1185548405
Principal investigator 1 Amgen Inc. $63,918.95 04/23/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246638590
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,445.20 04/01/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Postmarked Study for Flare Retreatment No dispute reported 06/30/2026 1220796459
Principal investigator 1 Amgen Inc. $58,973.48 03/25/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246638588
Principal investigator 1 AstraZeneca UK Limited $88,347.00 02/03/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or Intolerant to Antimalarial Therapy No dispute reported 06/30/2026 1185548403
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,882.00 01/31/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) No dispute reported 06/30/2026 1236000000
Principal investigator 1 Amgen Inc. $19,054.15 01/02/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ? 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) No dispute reported 06/30/2026 1246638594